tetano
Editor, Senior Moderator
Antiviral Res
. 2023 Dec 23:105785.
doi: 10.1016/j.antiviral.2023.105785. Online ahead of print. Broadly neutralizing antibodies to combat influenza virus infection
Xiaoyu Sun[SUP] 1 [/SUP], Hanwen Ma[SUP] 2 [/SUP], Xuanjia Wang[SUP] 2 [/SUP], Zhiheng Bao[SUP] 2 [/SUP], Shubing Tang[SUP] 3 [/SUP], Chunyan Yi[SUP] 4 [/SUP], Bing Sun[SUP] 5 [/SUP]
Affiliations
The diversified classification and continuous alteration of influenza viruses underscore for antivirals and vaccines that can counter a broad range of influenza subtypes. Hemagglutinin (HA) and neuraminidase (NA) are two principle viral surface targets for broadly neutralizing antibodies. A series of monoclonal antibodies, targeting HA and NA, have been discovered and characterized with a wide range of neutralizing activity against influenza viruses. Clinical studies have demonstrated the safety and efficacy of some HA stem-targeting antibodies against influenza viruses. Broadly neutralizing antibodies (bnAbs) can serve as both prophylactic and therapeutic agents, as well as play a critical role in identifying antigens and epitopes for the development of universal vaccines. In this review, we described and summarized the latest discoveries and advancements of bnAbs against influenza viruses in both pre- and clinical development. Additionally, we assess whether bnAbs can serve as a viable alternative to vaccination against influenza. Finally, we discussed the rationale behind reverse vaccinology, a structure-guided universal vaccine design strategy that efficiently identifies candidate antigens and conserved epitopes that can be targeted by antibodies.
Keywords: Broadly neutralizing antibody; Epitope-based vaccine design; Hemagglutinin; Influenza virus; Neuraminidase.
. 2023 Dec 23:105785.
doi: 10.1016/j.antiviral.2023.105785. Online ahead of print. Broadly neutralizing antibodies to combat influenza virus infection
Xiaoyu Sun[SUP] 1 [/SUP], Hanwen Ma[SUP] 2 [/SUP], Xuanjia Wang[SUP] 2 [/SUP], Zhiheng Bao[SUP] 2 [/SUP], Shubing Tang[SUP] 3 [/SUP], Chunyan Yi[SUP] 4 [/SUP], Bing Sun[SUP] 5 [/SUP]
Affiliations
- PMID: 38145757
- DOI: 10.1016/j.antiviral.2023.105785
The diversified classification and continuous alteration of influenza viruses underscore for antivirals and vaccines that can counter a broad range of influenza subtypes. Hemagglutinin (HA) and neuraminidase (NA) are two principle viral surface targets for broadly neutralizing antibodies. A series of monoclonal antibodies, targeting HA and NA, have been discovered and characterized with a wide range of neutralizing activity against influenza viruses. Clinical studies have demonstrated the safety and efficacy of some HA stem-targeting antibodies against influenza viruses. Broadly neutralizing antibodies (bnAbs) can serve as both prophylactic and therapeutic agents, as well as play a critical role in identifying antigens and epitopes for the development of universal vaccines. In this review, we described and summarized the latest discoveries and advancements of bnAbs against influenza viruses in both pre- and clinical development. Additionally, we assess whether bnAbs can serve as a viable alternative to vaccination against influenza. Finally, we discussed the rationale behind reverse vaccinology, a structure-guided universal vaccine design strategy that efficiently identifies candidate antigens and conserved epitopes that can be targeted by antibodies.
Keywords: Broadly neutralizing antibody; Epitope-based vaccine design; Hemagglutinin; Influenza virus; Neuraminidase.